AIP
PRLD icon

ARS Investment Partners’s Prelude Therapeutics PRLD Stock Holding History

ARS Investment Partners’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-7,400
Closed -$212K – 170
2021
Q2 		$212K Hold
7,400
– – 0.02% 134
2021
Q1 		$321K Hold
7,400
– – 0.04% 113
2020
Q4 		$529K Buy
+7,400
New +$368K 0.07% 82

Other funds holding PRLD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

ARS Investment Partners's PRLD Position: Q3 2021 in Review

ARS Investment Partners sold out of Prelude Therapeutics (PRLD) in Q3 2021, closing a stake of 7,400 shares — an estimated $212K sold.

ARS Investment Partners first reported a position in PRLD in Q4 2020 and held it in 3 quarters. The position peaked at $529K in Q4 2020. 61 funds tracked by Wall St. Rank hold PRLD as of Q3 2021.

  • ARS Investment Partners reported no remaining Prelude Therapeutics position as of Q3 2021 after selling out during the quarter.
  • ARS Investment Partners sold 7,400 Prelude Therapeutics shares in Q3 2021, an estimated $212K.
  • ARS Investment Partners first reported a position in Prelude Therapeutics in Q4 2020 and held it in 3 quarters.
  • ARS Investment Partners's Prelude Therapeutics position peaked at $529K in Q4 2020.
  • 61 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q3 2021.

Based on ARS Investment Partners's 13F filing for Q3 2021, filed 5 Nov 2021.